Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.

Journal of medicinal chemistry - 10 Sept 2015

Wu Fangrui, Jiang Hong, Zheng Baisong, Kogiso Mari, Yao Yuan, Zhou Chao, Li Xiao-Nan, Song Yongcheng

Abstract excerpt

Somatic mutations of isocitrate dehydrogenase 1 (IDH1) at R132 are frequently found in certain cancers such as glioma. With losing the activity of wild-type IDH1, the R132H and R132C mutant proteins can reduce α-ketoglutaric acid (α-KG) to d-2-hydroxyglutaric acid (D2HG). The resulting high conce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray
Share to Drug Screening Assays, Antitumor
Share to Glutarates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histones

Share to Isocitrate Dehydrogenase

Share to Methylation

Share to Neoplastic Stem Cells

Share to Thermodynamics

Source

Open in PubMed Open full text

Identifiers

PMID: 26280302
DOI: 10.1021/acs.jmedchem.5b00684
PMCID: PMC4567406

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-26280302-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.PMID 26280302Read ↗

Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.Semantic proximity Read ↗

Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.Semantic proximity Read ↗

Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.Semantic proximity Read ↗

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.Semantic proximity Read ↗

Isocitrate dehydrogenase gene variants in cancer and their clinical significance.Semantic proximity Read ↗

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Semantic proximity Read ↗

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.Semantic proximity Read ↗

Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach.Semantic proximity Read ↗

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular DifferentiationSemantic proximity Read ↗

Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.Semantic proximity Read ↗

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysSemantic proximity Read ↗

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.